HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

被引：118
|
作者：
Kemp, Troy J. [1 ]
Hildesheim, Allan [2 ]
Safaeian, Mahboobeh [2 ]
Dauner, Joseph G. [1 ]
Pan, Yuanji [1 ]
Porras, Carolina [3 ]
Schiller, John T. [4 ]
Lowy, Douglas R. [4 ]
Herrero, Rolando [3 ]
Pinto, Ligia A. [1 ]
机构：
[1] NCI Frederick, HPV Immunol Lab, SAIC Frederick Inc, Frederick, MD 21702 USA
[2] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA
[3] Fdn INCIENSA, Proyecto Epidemiol Guanacaste, San Jose, Costa Rica
[4] NCI, Cellular Oncol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
来源：
VACCINE | 2011年 / 29卷 / 11期
基金：
美国国家卫生研究院;
关键词：
Human papillomavirus; Antibody; Vaccine; PARTICLE VACCINE; YOUNG-WOMEN; INFECTION; EFFICACY; IMMUNIZATION; RESPONSES; TYPE-18; HPV-18;
D O I：
10.1016/j.vaccine.2011.01.001
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Human papillomavirus (HPV) L1 VLP-based vaccines are protective against HPV vaccine-related types; however, the correlates of protection have not been defined. We observed that vaccination with Cervarix (TM) induced cross-neutralizing antibodies for HPV types for which evidence of vaccine efficacy has been demonstrated (HPV31/45) but not for other types (HPV52/58). In addition, HPV31/45 cross-neutralizing titers showed a significant increase with number of doses (HPV31, p < 0.001; HPV45, p < 0.001) and correlated with HPV16/18 neutralizing titers, respectively. These findings raise the possibility that cross-neutralizing antibodies are effectors of cross-protection observed for the HPV16/18 vaccine.(C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2011 / 2014
页数：4
相关论文
共 48 条
  • [41] Comparative Analysis of HPV16 Variants in the Untranslated Regulatory Region, L1, and E6 Genes among Vaccinated and Unvaccinated Young Women: Assessing Vaccine Efficacy and Viral Diversity
    van Eer, Kahren
    Dzebisasjvili, Tsira
    Steenbergen, Renske D. M.
    King, Audrey J.
    VIRUSES-BASEL, 2024, 16 (09):
  • [42] Synthetic effect of folate deficiency, low expression of hnRNP E2 and down-regulation of HPV16 L1 and L2 proteins on cervical intraepithelial neoplasia: A cross-sectional study based on a Chinese community
    Han, Yang
    Ding, Ling
    Liu, Chunliang
    Jia, Wulin
    Lv, Yuanjing
    Wang, Ming
    Wang, Jintao
    ALEXANDRIA ENGINEERING JOURNAL, 2021, 60 (02) : 2619 - 2627
  • [43] NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice
    Sadr-Momtaz, Sahar
    Aftabi, Maryam
    Behboudi, Emad
    Naderi, Malihe
    Hashemzadeh-Omran, Anahita
    Moradi, Abdolvahab
    BMC RESEARCH NOTES, 2023, 16 (01)
  • [44] Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard (R)
    Halfon, Philippe
    Ravet, Sophie
    Khiri, Hacene
    Penaranda, Guillaume
    Lefoll, Carole
    CLINICAL MEDICINE INSIGHTS-CASE REPORTS, 2010, 3 : 69 - 71
  • [45] NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice
    Sahar Sadr-Momtaz
    Maryam Aftabi
    Emad Behboudi
    Malihe Naderi
    Anahita Hashemzadeh-Omran
    Abdolvahab Moradi
    BMC Research Notes, 16
  • [46] Development of influenza H7N9 virus like particle (VLP) vaccine: Homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus
    Smith, Gale E.
    Flyer, David C.
    Raghunandan, Ramadevi
    Liu, Ye
    Wei, Ziping
    Wu, Yingyun
    Kpamegan, Eloi
    Courbron, Denise
    Fries, Louis F., III
    Glenn, Gregory M.
    VACCINE, 2013, 31 (40) : 4305 - 4313
  • [47] Porcine Circovirus (PCV) Genotype 2d-Based Virus-like Particles (VLPs) Induced Broad Cross-Neutralizing Antibodies against Diverse Genotypes and Provided Protection in Dual-Challenge Infection of a PCV2d Virus and a Type 1 Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)
    Kang, Seok-Jin
    Bae, Sung-Min
    Lee, Hye-Jeong
    Jeong, Young-Ju
    Lee, Min-A
    You, Su-Hwa
    Lee, Hyang-Sim
    Hyun, Bang-Hun
    Lee, Nakhyung
    Cha, Sang-Ho
    PATHOGENS, 2021, 10 (09):
  • [48] A Dual-Type L2 11-88 Peptide from HPV Types 16/18 Formulated in Montanide ISA 720 Induced Strong and Balanced Th1/Th2 Immune Responses, Associated with High Titers of Broad Spectrum Cross-Reactive Antibodies in Vaccinated Mice
    Khiavi, Farhad Motavalli
    Arashkia, Arash
    Golkar, Majid
    Nasimi, Maryam
    Roohvand, Farzin
    Azadmanesh, Kayhan
    JOURNAL OF IMMUNOLOGY RESEARCH, 2018, 2018
12345